{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T18:20:09Z","timestamp":1789669209414,"version":"4.0.1"},"reference-count":23,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[1995,6,1]],"date-time":"1995-06-01T00:00:00Z","timestamp":801964800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[1995,6]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To describe a probable case of transient global amnesia caused by propafenone. This adverse effect has not been previously described for this agent.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case Summary:<\/jats:title>\n                    <jats:p>A 61-year-old man with a history of sick sinus syndrome with persistent atrial fibrillation and infrequent premature ventricular contractions was admitted to the hospital for symptoms of amnesia and disorientation to time, place, and date. He began taking propafenone only 6 days prior to admission because of uncontrolled atrial fibrillation and symptoms of fatigue. His atrial fibrillation subsequently had converted to normal sinus rhythm while he received propafenone without adverse effects prior to this episode. His symptoms of amnesia resolved approximately 6\u20137 hours after discontinuing the propafenone therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion:<\/jats:title>\n                    <jats:p>Propafenone is a class 1C antiarrhythmic agent that blocks fast sodium channels in heart muscle and Purkinje fibers similar to the action of encainide and flecainide. It also produces weak beta- and calcium-channel blockade. It has a significant adverse effect profile, with 30\u201345% of patients reporting cardiac adverse effects and 15\u201320% experiencing noncardiac events. Central nervous system effects that parallel amnesia have been reported in 10\u201315% of the patients, including dizziness, ataxia, drowsiness, fatigue, confusion, and paranoia. Propafenone's distribution, clearance, and structural similarity to propranolol contribute to its central nervous system effects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>The rapid resolution of this patient's symptoms after discontinuing propafenone therapy and the absence of recurrence lend credence to the probability of this effect. Comparable adverse effects, such as disorientation and temporary amnesia, have been reported in patients on the analogous agent, propranolol. Consequently, this is a likely, although rare, possible adverse effect with propafenone for which patients should be monitored.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/106002809502900606","type":"journal-article","created":{"date-parts":[[2017,1,13]],"date-time":"2017-01-13T10:24:44Z","timestamp":1484303084000},"page":"586-590","source":"Crossref","is-referenced-by-count":14,"title":["Probable Propafenone-Induced Transient Global Amnesia"],"prefix":"10.1177","volume":"29","author":[{"given":"Ronald J","family":"Jones","sequence":"first","affiliation":[{"name":"Ohio Northern University, Ada, OH, and Clinical Practitioner\/Educator, Lutheran Hospitals of Indiana, Fort Wayne, IN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven R","family":"Brace","sequence":"additional","affiliation":[{"name":"Lutheran Hospitals of Indiana, and Adjunct Professor of Clinical Pharmacy, Ohio Northern University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elton L","family":"Vander Tuin","sequence":"additional","affiliation":[{"name":"Lutheran Hospitals of Indiana, and Adjunct Professor Clinical Pharmacy, Ohio Northern University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[1995,6,1]]},"reference":[{"key":"bibr1-106002809502900606","doi-asserted-by":"crossref","unstructured":"ReimerA, ThomasP, Hans-CarloK. Efficacy and safety of intravenous and oral propafenone in pediatric cardiac dysrhythmias. Am J Cardiol 1991;68:741-4.","DOI":"10.1016\/0002-9149(91)90646-3"},{"key":"bibr2-106002809502900606","doi-asserted-by":"crossref","unstructured":"DinhH, BakerBJ, DesoyzaN, MurphyML. Sustained therapeutic efficacy and safety of oral propafenone for treatment of chronic ventricular arrhythmias: a 2 year experience. Am Heart J 1988;115:92-6.","DOI":"10.1016\/0002-8703(88)90522-4"},{"key":"bibr3-106002809502900606","doi-asserted-by":"crossref","unstructured":"SchlepperM. Propafenone: a review of its profile. Eur Heart J 1987; 8 (suppl A):27-32.","DOI":"10.1093\/eurheartj\/8.suppl_A.27"},{"key":"bibr4-106002809502900606","unstructured":"RobinsonAJ. Paranoia after propafenone (letter). Pharm J 1991;247:556."},{"key":"bibr5-106002809502900606","unstructured":"FisherCM, AdamsRD. Transient global amnesia. Acta Neurol Scand 1964;40(suppl):9-15."},{"key":"bibr6-106002809502900606","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154"},{"key":"bibr7-106002809502900606","doi-asserted-by":"crossref","unstructured":"CarrollS, LebrachC, WinkleRA, HarrisoneDC, KatesRE. Propafenone disposition kinetics in cardiac arrhythmia. Clin Pharmacol Ther 1984;36:163-8.","DOI":"10.1038\/clpt.1984.157"},{"key":"bibr8-106002809502900606","unstructured":"HollmannM, BrodeE, HotzD, KaumeierS, KehrhahnOH. Investigations on the pharmacokinetics of propafenone in man. Arzneimittelforschung 1983;33:763-70."},{"key":"bibr9-106002809502900606","doi-asserted-by":"crossref","unstructured":"SiddowayLA, ThompsonKA, McAllisterCB, WangT, WilkinsonGR, RodenDM, Polymorphism of propafenone metabolism and disposition in man: clinical and pharmacokinetic consequences. Circulation 1987;75:785-91.","DOI":"10.1161\/01.CIR.75.4.785"},{"key":"bibr10-106002809502900606","doi-asserted-by":"crossref","unstructured":"KatesRE, YeeYG, WinkleRA. Metabolite cumulation during chronic propafenone dosing in arrhythmia. Clin Pharmacol Ther 1985;37:610-4.","DOI":"10.1038\/clpt.1985.97"},{"key":"bibr11-106002809502900606","doi-asserted-by":"crossref","unstructured":"LeeJT, YeeYG, DorianP, KatesRE. Influence of hepatic dysfunction on pharmacokinetics of propafenone. J Clin Pharmacol 1987;27:384-9.","DOI":"10.1002\/j.1552-4604.1987.tb03035.x"},{"key":"bibr12-106002809502900606","doi-asserted-by":"crossref","unstructured":"KroemerHK, MikusG, KronbachT, MeyerUA, EichelbaumM. In vitro characterization of the human cytochrome P450 involved in polymorphic oxidation of propafenone. Clin Pharmacol Ther 1989;45:28-33.","DOI":"10.1038\/clpt.1989.5"},{"key":"bibr13-106002809502900606","doi-asserted-by":"crossref","unstructured":"BigotM, DebruyneD, BonnefoyL, GrollierG, MoulinM, PotierJ. Serum digoxin levels related to plasma propafenone levels during concomitant treatment. J Clin Pharmacol 1991;31:521-6.","DOI":"10.1002\/j.1552-4604.1991.tb03731.x"},{"key":"bibr14-106002809502900606","doi-asserted-by":"crossref","unstructured":"CalvoMV, Martin-SuarezA, Martin LuengoC, AvilaC, CasconM, HurleA. Interaction between digoxin and propafenone. Ther Drug Monit 1989;11:10-5.","DOI":"10.1097\/00007691-198901000-00003"},{"key":"bibr15-106002809502900606","doi-asserted-by":"crossref","unstructured":"RinkenbergerRL. Efficacy and safety of class IC antiarrhythmic agents for the the treatment of coexisting supraventricular and ventricular tachycardia. Am J Cardiol 1988;62(suppl):44D-55D.","DOI":"10.1016\/0002-9149(88)90507-3"},{"key":"bibr16-106002809502900606","doi-asserted-by":"crossref","unstructured":"HohnloserSH, ZabelM. Short- and long-term efficacy and safety of flecainide acetate for supraventricular arrhythmias. Am J Cardiol 1992; 70(suppl):3A-10A.","DOI":"10.1016\/0002-9149(92)91071-B"},{"key":"bibr17-106002809502900606","doi-asserted-by":"crossref","unstructured":"PuechP, GagnolJP. Class IC drugs: propafenone and flecainide. Cardiovasc Drugs Ther 1990;4(suppl 3):549\u201353.","DOI":"10.1007\/BF00357028"},{"key":"bibr18-106002809502900606","doi-asserted-by":"crossref","unstructured":"LeddaF, MantelliL, ManziniS, AmeriniS, MugellaA. Electrophysiological and antiarrhythmic properties of propafenone in isolated cardiac preparations. J Cardiovasc Pharmacol 1981;3:1162-73.","DOI":"10.1097\/00005344-198111000-00002"},{"key":"bibr19-106002809502900606","doi-asserted-by":"crossref","unstructured":"McLeodA A, StilesGL, ShandDG. Demonstration of beta adrenoreceptor blockade by propafenone hydrochloride: clinical pharmacologic, radioligand binding and adenylate cyclase activation studies. J Pharmacol Exp Ther 1984;228:461-6.","DOI":"10.1016\/S0022-3565(25)21760-8"},{"key":"bibr20-106002809502900606","doi-asserted-by":"crossref","unstructured":"KoellaWP. CNS-related (side-) effects of beta-blockers with special reference to mechanisms of action. Eur J Pharmacol 1985;28(suppl): 55-63.","DOI":"10.1007\/BF00543711"},{"key":"bibr21-106002809502900606","unstructured":"BullingerM. Psychotropic effects of non-psychotropic drugs. Adverse Drug React Acute Pois Rev 1987;3:141-67."},{"key":"bibr22-106002809502900606","doi-asserted-by":"crossref","unstructured":"FisherCM. Amnestic syndrome associated with propranolol toxicity: a case report. Clin Neuropharmacol 1992;15:397-403.","DOI":"10.1097\/00002826-199210000-00008"},{"key":"bibr23-106002809502900606","doi-asserted-by":"crossref","unstructured":"GoodMI. Organic dissociative syndrome associated with antimigraine pharmacotherapy. Can J Psychiatry 1991;36:597-9.","DOI":"10.1177\/070674379103600810"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/106002809502900606","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/106002809502900606","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:07:19Z","timestamp":1777374439000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/106002809502900606"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1995,6]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[1995,6]]}},"alternative-id":["10.1177\/106002809502900606"],"URL":"https:\/\/doi.org\/10.1177\/106002809502900606","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[1995,6]]}}}